Home Cart Sign in  
Chemical Structure| 1799753-84-6 Chemical Structure| 1799753-84-6

Structure of BAY-876
CAS No.: 1799753-84-6

Chemical Structure| 1799753-84-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BAY-876 is a selective inhibitor of GLUT1 with IC50 of 0.002 μM with good metabolic stability.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BAY-876

CAS No. :1799753-84-6
Formula : C24H16F4N6O2
M.W : 496.42
SMILES Code : O=C(C1=NC2=CC(F)=CC=C2C(C(NC3=C(C)N(CC4=CC=C(C#N)C=C4)N=C3C(F)(F)F)=O)=C1)N
MDL No. :MFCD30377201
InChI Key :BKLJDIJJOOQUFG-UHFFFAOYSA-N
Pubchem ID :118191391

Safety of BAY-876

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • GLUT1

    GLUT1, IC50:0.002 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
HC11 cells 100 nM 24 hours No obvious negative impact on GLUT1-normal cell populations PMC10622423
MDA-MB-468 3 µM 72 hours No significant changes in cell cycle observed PMC7442809
MDA-MB-436 3 µM 72 hours No significant changes in cell cycle observed PMC7442809
DU145 cells 25 µM, 12 µM, 6 µM, 3 µM, 1.5 µM, 0.7 µM 0, 24, 48, 72 hours To evaluate the inhibitory effect of BAY-876 on the viability of prostate cancer cells. Results showed that as the concentration of BAY-876 increased, cell activity gradually weakened. The IC50 of PC-3 at 24 h was 0.70 µM, and that of DU145 was 2.19 µM. PMC11515740
PC-3 cells 25 µM, 12 µM, 6 µM, 3 µM, 1.5 µM, 0.7 µM 0, 24, 48, 72 hours To evaluate the inhibitory effect of BAY-876 on the viability of prostate cancer cells. Results showed that as the concentration of BAY-876 increased, cell activity gradually weakened. The IC50 of PC-3 at 24 h was 0.70 µM, and that of DU145 was 2.19 µM. PMC11515740
HaCaT cells 1 mM 2 hours To evaluate the inhibitory effect of BAY-876 on Glu-4-ZnPc uptake in HaCaT cells PMC11207564
Primary Gingival Keratinocytes 10 nM to 100 µM 24 hours BAY-876 inhibited glucose uptake in primary gingival keratinocytes and reduced cell viability. PMC11282258
FaDu 10 nM to 100 µM 24 hours BAY-876 inhibited glucose uptake in FaDu cells, reduced cell viability and metabolism, and induced apoptosis. PMC11282258
RPMI2650 10 nM to 100 µM 24 hours BAY-876 inhibited glucose uptake in RPMI2650 cells, reduced cell viability and metabolism, and induced apoptosis. PMC11282258
SCC47 10 nM to 100 µM 24 hours BAY-876 inhibited glucose uptake in SCC47 cells, reduced cell viability and metabolism, and induced apoptosis. PMC11282258
4T1 cells 100 nM 24 hours Inhibited glycolysis activity in 4T1 cells, reduced PD-L1 glycosylation levels, and enhanced the binding affinity of aptPD-L1 to PD-L1 PMC10622423
HCT116 cells 1 μM 24 hours BAY-876 inhibited the proliferation of HCT116 cells with an IC50 of 0.1–0.2 µmol/L. PMC11010912
LS174T cells 1 μM 24 hours BAY-876 inhibited the proliferation of LS174T cells with an IC50 of 0.1–0.2 µmol/L. PMC11010912
HEK293 cells 0.05 μM, 1 μM, 5 μM 30 minutes To assess the inhibitory effect of BAY-876 on glucose uptake mediated by GLUT1-6 and GLUT10. Results showed BAY-876 inhibited glucose uptake via GLUT1, GLUT3, GLUT4, GLUT6, and GLUT10, but not GLUT2. PMC9776291
HEK293 cells 0.05 μM, 1 μM, 5 μM 30 minutes To assess the ability of BAY-876 to inhibit hexose uptake via facilitative glucose transporters. Results showed BAY-876 inhibited glucose uptake via GLUT1, GLUT3, GLUT4, GLUT6, and GLUT10, but not GLUT2. PMC9776291
HepG2 cells 1 μM 48 hours BAY-876 significantly inhibited the expression of glycogenesis-related genes GBE1, GYS1, UGP2, and glycogenolysis-related gene PYGM PMC10339511
Huh7 cells 1 μM 48 hours BAY-876 significantly inhibited the expression of glycogenesis-related genes GBE1, GYS1, UGP2, and glycogenolysis-related gene PYGM PMC10339511
Pt2377 25-400 nM 5 days BAY-876 inhibited the proliferation of Pt2377 cells. PMC9081236
LS174T 25-400 nM 5 days BAY-876 inhibited the proliferation of LS174T cells. PMC9081236
Hs 578T 3 µM 72 hours Inhibited cell growth and proliferation, increased cell cycle arrest and apoptosis PMC7442809
HCC1806 3 µM 72 hours Inhibited cell growth and proliferation, increased cell cycle arrest and apoptosis PMC7442809
UMRC6 cells 2 μM Measure cell death, results showed BAY-876 significantly increased death in SLC7A11-high cells PMC7194135
786-O cells 2 μM Measure glucose uptake levels and NADP+/NADPH ratios, results showed BAY-876 significantly inhibited glucose uptake and increased NADP+/NADPH ratios PMC7194135
GL261 cells 2 nM 72 hours Inhibit GLUT1 expression and reduce lactate excretion PMC11095231

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Balb/c mice 4T1 tumor model Intravenous injection 0.05 µg/mL/g Once every two days for 21 days Significantly inhibited tumor growth, reduced lactic acid and UDP-GlcNAc levels in the tumor microenvironment, and enhanced anti-tumor immune responses PMC10622423
Mice Muscle-specific GLUT1 knockout mice In vitro muscle incubation 0.05 μM, 1 μM, 5 μM 60 minutes To evaluate the effect of BAY-876 on basal and overload-stimulated muscle glucose uptake. Results showed that low-dose BAY-876 (0.05 μM) completely impaired overload-stimulated glucose uptake but did not affect basal uptake. PMC9776291
Mice Muscle-specific GLUT1 knockout (mGLUT1KO) mice Ex vivo muscle incubation 0.05 μM, 1 μM, 5 μM 60 minutes To assess the effect of BAY-876 on basal and overload-stimulated muscle glucose uptake. Results showed that a low dose of BAY-876 (0.05 μM) completely impaired overload-stimulated but not basal glucose uptake. PMC9776291
C57BL/6 mice STZ-induced hyperglycemic model Intravenous injection 1.0 mg/kg Daily injections for 16 days BAY-876 significantly reduced STZ-induced astrocyte proliferation but had no effect on microglia numbers PMC11131277
Balb/c mice 4T1 breast tumor xenograft model Tail vein injection 10 mg/kg Single dose, monitored for 14 days Evaluate the in vivo antitumor efficacy and biodistribution of CFMB, showing significant tumor growth suppression without systemic toxicity. PMC11187878
Mice NCI-H226 xenograft tumors Intraperitoneal injection 100 mg/kg Every two days Evaluate the therapeutic effect of GLUT inhibitors on SLC7A11-high tumors, results showed BAY-876 significantly suppressed tumor growth PMC7194135
Mice PDX model Oral 2 mg/kg daily Once daily for 30 days Impaired tumor growth with no significant loss of body weight PMC7442809
C57BL/6J mice Subcutaneous GBM model Subcutaneous injection 2 nM 21 days Inhibit lactate excretion and delay tumor growth PMC11095231
Nude mice HCC xenograft model Gavage 2.5 mg/kg Every 3 days for 28 days BAY-876 significantly inhibited BMP4-induced subcutaneous tumor growth and glycogen accumulation PMC10339511
RAG1−/−γc− mice LS174T cell xenograft model Oral administration 3 mg/kg/day Once daily for 12 days BAY-876 significantly inhibited tumor growth in the LS174T cell xenograft model. PMC11010912
SCID mice LS174T xenograft model Oral (BAY-876), Intraperitoneal (DBI-1) 3 mg/kg/day (BAY-876), 40 mg/kg/day (DBI-1) Once daily for 12 days BAY-876 and DBI-1 alone or in combination inhibited tumor growth, with combination therapy being more effective than either compound alone. PMC9081236

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.01mL

0.40mL

0.20mL

10.07mL

2.01mL

1.01mL

20.14mL

4.03mL

2.01mL

References

 

Historical Records

Categories